Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Emergent Biosolutions 300 Professional Drive GAITHERSBURG MD 20879 USA

www.emergentbiosolutions.com P: 240-631-3200

Description:

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.

Key Statistics

Overview:

Market Capitalization, $K 127,375
Enterprise Value, $K 875,875
Shares Outstanding, K 52,203
Annual Sales, $ 1,049 M
Annual Net Income, $ -760,500 K
Last Quarter Sales, $ 275,800 K
Last Quarter Net Income, $ -52,800 K
EBIT, $ -442,600 K
EBITDA, $ -78,000 K
60-Month Beta 1.22
% of Insider Shareholders 1.90%
% of Institutional Shareholders 78.40%
Float, K 51,211
% Float 98.10%
Short Volume Ratio 0.36

Growth:

1-Year Return -70.77%
3-Year Return -96.78%
5-Year Return -95.14%
5-Year Revenue Growth 34.11%
5-Year Earnings Growth -367.38%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.77 on 03/06/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -6.44
EPS Growth vs. Prev Qtr 46.53%
EPS Growth vs. Prev Year -148.39%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

EBS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -37.36%
Return-on-Assets % -14.80%
Profit Margin % -72.48%
Debt/Equity 1.32
Price/Sales 0.13
Price/Cash Flow 2.74
Price/Book 0.19
Book Value/Share 12.52
Interest Coverage -7.32
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar